Topoisomerase II alpha (Topo IIa) plays an important role in DNA synthesis and RNA transcription, as well as chromosomal segregation during mitosis. It is reported to be a sensitive and specific marker of late S-, G2- & M-phases in transformed and developmentally regulated normal cells. Topo IIa is also implicated in drug resistance of tumor cells and has been shown to be over-expressed in many human cancers. Decreased expression of Topo IIa is the predominant mechanism of resistance to several chemotherapeutic agents.
1. Gao XH, et al. DNA topoisomerase II alpha: a favorable prognostic factor in colorectal cancer. Int J Colorectal Dis. 2011 Nov 12.
2. Nikolényi A, et al. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer. Oncology. 2011; 80(3-4):269-77. Epub 2011 Jul 7.
3. Karnes RJ, et al. The ability of biomarkers to predict systemic progression in men with high-risk prostate cancer treated surgically is dependent on ERG status. Cancer Res. 2010 Nov 15; 70(22):8994-9002. Epub 2010 Nov 9.
4. Ferrandina G, et al. Prognostic role of topoisomerase-II alpha in advanced ovarian cancer patients. Br J Cancer. 2008 Jun 17; 98(12):1910-5. Epub 2008 May 27.
5. Kim EJ, et al. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer. Urology. 2010 Jun; 75 (6):1516.e9-13. Epub 2009 Nov 13.
6. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 “Decontamination of Laboratory Sink Drains to Remove Azide Salts.”
7. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory Workers from Occupationally Acquired Infections; Approved guideline-Third Edition CLSI document M29-A3 Wayne, PA 2005.